Dr. Daniel Combs, MD
Sleep Medicine (Pediatric Sleep Medicine Physician)
1501 N Campbell Ave
Tucson, AZ 85724
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 13
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Arizona College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Sleep Medicine Physician primary
AZ license 48789 -
Pediatrics Physician
AZ license R72754
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 13
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $398 in total to this clinician.
| Avadel Cns Pharmaceuticals, LLC | $207 |
|---|---|
| Jazz Pharmaceuticals Inc. | $150 |
| Amgen Inc. | $40.52 |
| Consulting Fee | $350 |
|---|---|
| Food and Beverage | $47.76 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Avadel Cns Pharmaceuticals, LLC Apr 21, 2025 | Consulting Fee LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY · in-kind | $200 |
| Jazz Pharmaceuticals Inc. Jan 10, 2025 | Consulting Fee XYWAV; XYREM · NEUROLOGY | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $14,430 in research payments for these studies, mostly to the institutions running them.
- Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
Idorsia Pharmaceuticals US Inc · Completed · NCT05423717
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.